Amantadine: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Antiviral]], [[anticholinergics]] | *Type: [[Antiviral]], [[anticholinergics]] | ||
*Dosage Forms: | *Dosage Forms: capsule or tablet, syrup | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
*Common Trade Names: | *Common Trade Names: Gocovri | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 11: | Line 11: | ||
===Parkinsonism, extrapyramidal disease=== | ===Parkinsonism, extrapyramidal disease=== | ||
*100-200 mg BID | *100-200 mg BID | ||
===[[Neuroleptic malignant syndrome]]=== | |||
*100mg PO initially | |||
*Titrate up as needed to max dose 200mg q12hr | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 18: | Line 22: | ||
===[[Influenza]], >9 years old=== | ===[[Influenza]], >9 years old=== | ||
*100 mg PO BID | *100 mg PO BID | ||
==Special Populations== | ==Special Populations== | ||
| Line 53: | Line 53: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 10-25h | *Half-life: 10-25h | ||
*Metabolism: | *Metabolism: Not appreciably metabolized; small amounts of acetyl metabolite identified | ||
*Excretion: Renal | *Excretion: Renal | ||
| Line 68: | Line 68: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] [[Category:Neurology]] | ||
Latest revision as of 16:46, 19 September 2019
Administration
- Type: Antiviral, anticholinergics
- Dosage Forms: capsule or tablet, syrup
- Routes of Administration: Oral
- Common Trade Names: Gocovri
Adult Dosing
Influenza A
- 100 mg BID or 200 mg daily PO
Parkinsonism, extrapyramidal disease
- 100-200 mg BID
Neuroleptic malignant syndrome
- 100mg PO initially
- Titrate up as needed to max dose 200mg q12hr
Pediatric Dosing
Influenza, 1-9 years old
- 2.2-4.4 mg/kg PO BID
Influenza, >9 years old
- 100 mg PO BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- CrCl 30-50 mL/min: 200 mg PO on first day, then 100 mg/day
- CrCl 15-29 mL/min: 200 mg PO on first day, then 100 mg every other day
- CrCl <15 mL/min or on HD: 200mg weekly
- Hepatic dosing: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- CHF, hypotension, dysrhythmia, tachycardia, cardiac arrest
- Pulmonary edema, acute respiratory failure
- Malignant melanoma
- Leukopenia, agranulocytosis, neutropenia
- Neuroleptic malignant syndrome
- Suicidal ideation
Common
- Nausea, diarrhea, constipation, lack of appetite
- Headache
- Fatigue, dizziness, confusion, ataxia
- Anxiety, insomnia, depression, irritability, hallucinations, dream disorder
- Orthostatic hypotension
- Peripheral edema
Pharmacology
- Half-life: 10-25h
- Metabolism: Not appreciably metabolized; small amounts of acetyl metabolite identified
- Excretion: Renal
Mechanism of Action
- Interferes with the function of viral M2 protein, preventing release of viral nucleic acids into host cell